Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCuttm - the world's first ...

First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treati ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today ...

As people age, a buildup of calcium on the aortic valve can make it thicker and stiffer leading to aortic stenosis. In addition, congenital heart defects, rheumatic fever, bacterial infections ...

In patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) with stable coronary ...